Also keep in mind deals take 4 to 6 months to close.....It's not like when a company is acquired you hand over keys to the acquirer the next day. Deals take months to close.
Again regulatory clock in Europe has started this past March......
But they can be directed also with other BP in mind not just Pfizer
So a stab at some answers .....
Amarin a steal ???? - with a share price of 5 which has been roughly where we have been running for a year many would suggest the BO cost is presently and has been for some time such to encourage a steal Would a cost equivalent to10 ps take it though ? Do big shareholders / the board think it worth more- at least 15 - I suspect so But to attain that level does not litigation hangover fog the air as to USA market and as European market it is only just setting up - and other usage of V may yet take shape -so BP can sit on hands for a while and watch
As to GIA - Amarin will until it is not - no choice - but the right money buys any company !! However over time much can happen to improve the companies position and maybe move the needle
My view is that KM and the company are way to quiet - but time required to get ducks in a row
In a few months - maybe by 2022 we will start to hear a concerted noise from Amarin
rafs Pfizer post says it all !!!
As to HLS -is no harm to Pfizer but it does give hands on selling of the drug as a precursor to BO if they wish or other possible arrangements
RMB. well the obvious reason to do the HLS deal ( besides keeping their cardio sales team employed ) is for PFE to get some real world experience in trying to get MD's to prescribe V, given that Health Canada will apparently cover for secondary prevention and diabetics with CV risk ...at least thats what I remember of your messaging with PD .
HLS is still going to market to Cardiologists ...PFE to regular MD's. ( FM ) and I believe PD gave you some time line for when the various provinces will cover
Partly OT ( ie still in the Cardio field ) ...SWAV at TCT 2021 Nov 4-5th
News 
Market Data 
Discover 
AI
